NSE:SOLARA (India)
Â
Ordinary Shares
₹
523.6
+4.35 (+0.84%)
Apr 17
What is a stock summary page? Click here for an overview.
Business Description
Solara Active Pharma Sciences Ltd
ISIN : INE624Z01016
Share Class Description:
NSE:SOLARA: Ordinary SharesCompare
Compare
Traded in other countries / regions
541540.India IPO Date
2018-06-27Description
Solara Active Pharma Sciences Ltd is engaged in Active Pharmaceutical Ingredients manufacturer (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinod, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant and others. It also offers contract services including contract development and manufacturing, analytical services. The group has a business presence in the Asia Pacific, Europe, North America, South America, and other places, of which the majority of income is generated from the Asia Pacific countries.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.02 | |||||
| Equity-to-Asset | 0.47 | |||||
| Debt-to-Equity | 0.77 | |||||
| Debt-to-EBITDA | 18.27 | |||||
| Interest Coverage | 0.65 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.4 | |||||
| Beneish M-Score | -4.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -9.2 | |||||
| 3-Year Book Growth Rate | -16.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 12.78 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.03 | |||||
| 9-Day RSI | 56.01 | |||||
| 14-Day RSI | 53.55 | |||||
| 3-1 Month Momentum % | -29.95 | |||||
| 6-1 Month Momentum % | -41.51 | |||||
| 12-1 Month Momentum % | 20.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.72 | |||||
| Quick Ratio | 0.45 | |||||
| Cash Ratio | 0.02 | |||||
| Days Inventory | 209.13 | |||||
| Days Sales Outstanding | 121.53 | |||||
| Days Payable | 163.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 | |||||
| Shareholder Yield % | 3.37 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.29 | |||||
| Operating Margin % | 5.63 | |||||
| Net Margin % | -20.06 | |||||
| FCF Margin % | 5.38 | |||||
| ROE % | -21.76 | |||||
| ROA % | -10.09 | |||||
| ROIC % | 4.51 | |||||
| 3-Year ROIIC % | -140.73 | |||||
| ROC (Joel Greenblatt) % | -3.26 | |||||
| ROCE % | -4.01 | |||||
| Years of Profitability over Past 10-Year | 4 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 15.98 | |||||
| PS Ratio | 1.71 | |||||
| PB Ratio | 2.32 | |||||
| Price-to-Tangible-Book | 3.67 | |||||
| Price-to-Free-Cash-Flow | 30.17 | |||||
| Price-to-Operating-Cash-Flow | 18.8 | |||||
| EV-to-EBIT | -56.01 | |||||
| EV-to-EBITDA | 66.07 | |||||
| EV-to-Revenue | 2.4 | |||||
| EV-to-FCF | 44.11 | |||||
| Price-to-GF-Value | 1.04 | |||||
| Price-to-Projected-FCF | 5.23 | |||||
| Earnings Yield (Greenblatt) % | -1.78 | |||||
| FCF Yield % | 3.07 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers